Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Vale SA (VALE) Price & Performance

Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Vale SA — how do they compare? Quest Diagnostics Inc trades at $230.77 (market cap $25.48B), while Vale SA trades at $13.55 (market cap $57.32B). The key difference: Vale SA is far larger — about 2.2× Quest Diagnostics Inc's market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Vale SA for 109 Days on average.

DGXVALE
Market Cap
$25.48B$57.32B
Volume
941,86627,996,846
Sector
HealthBasic Materials
52-Week High
$247.45$17.82
52-Week Low
$173.49$10.75
Typical Hold Time
56 Days109 Days
Enterprise Value
$31.23B$73.56B
Dividend Yield
1.49%8.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.

The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.

Vale SA

VALE trades at $13.50, down 0.81% with bearish technical signals. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 EPS expected at $0.42. Revenue declined from $43.8B in 2022 to $38.4B in 2025, though 2026 projections show a slight recovery to $41.2B. Analyst consensus is mixed with 32% buy ratings but a $16.21 price target suggesting 20% upside. Recent news highlights cost pressures and regulatory risks in Brazil.

VALE faces headwinds from declining iron ore margins and rising operational costs, but maintains strong cash flow and dividend payments. The base metals segment shows growth potential, though cyclical exposure and Brazilian regulatory uncertainty pose significant risks. With current valuation metrics appearing reasonable (P/E 26.8, P/B 1.5), the stock offers value for patient investors willing to navigate commodity volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DGX

No sentiment data available yet.

VALE
83% Buy17% Sell
Avg holding period · 109 Days

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →

About Vale SA

Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.

Read more on VALE →